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Abstract 
Background: Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological 
complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of 
these patients together with the immune-modulating activities of NC drugs suggest a potential contribution of host 
immunity in mediating clinical responses. We thus performed an extensive immunomonitoring in locally advanced 
BC patients undergoing NC to identify immunological correlates of pCR induction.
Methods: The immune profile of 40 HER2-positive and 38 HER2-negative BC patients was characterized at diagno-
sis and throughout NC (Paclitaxel and Trastuzumab, or Docetaxel and Epirubicin, respectively). The percentages of 
circulating immune cell subsets including T and B lymphocytes, Natural Killer (NK) cells, regulatory T cells, T helper 
17 lymphocytes, were quantified by multiparametric flow cytometry. NK cells functional activity was evaluated 
through the analysis of NF-kB nuclear translocation by Multispectral flow cytometry, and with the in vitro monitoring 
of Trastuzumab-mediated antibody-dependent cell cytotoxicity (ADCC). CD8+ T cell responses against six different 
tumor-associated antigens (TAA) were characterized by IFN-γ ELISPOT and IFN-γ/IL-2 DualSpot assays.
Results: After NC, HER2-positive patients showed a significant increase in the number of NK cells and regulatory T 
cells irrespective of the pathological response, whereas patients undergoing a pCR disclosed higher percentages of T 
helper 17 cells. Notably, a significant increase in the number of activated NK cells was observed only in HER2-positive 
patients achieving a pCR. Characterization of anti-tumor T cell responses highlighted sustained levels of CD8+ T cells 
specific for survivin and mammaglobin-A throughout NC in patients undergoing a pCR in both arms. Moreover, 
HER2-positive patients achieving a pCR were characterized by a multi-epitopic and polyfunctional anti-tumor T cell 
response, markedly reduced in case of partial response.
Conclusions: These results indicate that maintenance of functional T cell responses against selected antigens and 
improvement of NK cell proficiency during NC are probably critical requirements for pCR induction, especially in 
HER2-positive BC patients.
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Background
Breast cancer (BC) is characterized by a complex biologi-
cal heterogeneity, also reflected in the clinical setting in 
which distinct tumor subtypes show different rates of 
pathological complete response (pCR) induction after 
neoadjuvant chemotherapy (NC). The highest pCR odds 
are achieved in patients with triple negative (TN) or 
HER2-positive/hormone receptor-negative BCs [1]. Neo-
adjuvant therapy trials provide an ideal platform to iden-
tify biomarkers of possible predictive and/or prognostic 
significance, and pCR thus represents an endpoint for the 
rapid triage of drugs that may be helpful for subsequent 
adjuvant purposes [2].
In locally advanced BC patients treated with NC, the 
content of Tumor Infiltrating Lymphocytes (TILs) in the 
primary biopsy was shown to predict pCR [3, 4], espe-
cially in the TN and HER2-positive subsets [5, 6]. In 
these patients, taxane-based NC was shown to increase 
the number of tumor infiltrating CD8+ T cells [7, 8] 
and to induce their activation through the expression 
of Granzyme B [9]. Notably, a pronounced lymphocytic 
infiltration observed after treatment correlated with an 
improved outcome [8].
Besides playing an important role in tumor surveillance 
and modulation of tumor growth [10, 11], innate and 
adaptive immunity may also be involved in the response 
to chemotherapy as suggested by several trascriptomes 
analyses of mammary carcinomas [12]. Indeed, the 
destruction of tumor cells by chemotherapeutic agents 
may release tumor-associated antigens (TAAs), which, in 
turn, can trigger immune responses against tumor cells. 
This immunotherapeutic effect induced by chemotherapy 
may be particularly strong in patients already spontane-
ously sensitized against tumor antigens, thus potentially 
leading to a pCR [13, 14]. Notably, innate and adaptive 
immune mechanisms are emerging as key players also in 
the modulation of the activity of HER2-targeted drugs, 
such as the monoclonal antibody (moAb) Trastuzumab 
[5]. Indeed, higher efficiency of Antibody Dependent Cell 
Cytotoxicity (ADCC) and Natural Killer (NK) cell lysis 
were reported in clinical responders to Trastuzumab if 
compared with non-responders [15, 16]. Interestingly, 
the efficacy of Trastuzumab treatment was associated 
with the enhanced in situ infiltration of interferon-γ pro-
ducing CD8+ T cells [17–19] and CD4+ T helper (Th) 
lymphocytes [20], and decreased numbers of circulating 
regulatory T cells (Treg)/CD4+ [21] and reduced Treg/
inflammatory Th17 ratios [22].
In agreement with these findings, our recent charac-
terization of the immune profile of 61 locally advanced 
BC patients eligible for a NC schedule demonstrated 
that, at diagnosis, patients with HER2-overexpressing 
cancers had a retained immune proficiency and higher 
CD8+ T cell responses against several TAAs if compared 
to HER2-negative cases, whose general immune back-
ground, on the contrary, appeared compromised [23].
In the present study, we report on the results of the 
phenotypic and functional characterization of circulating 
immune cells in the same cohort of BC patients through-
out NC treatment, based on the use of Paclitaxel and 
Trastuzumab in the HER2-positive arm and Epirubicin 
and Docetaxel in HER2-negative patients. Our main 
objective was to gain insights on the possible contribu-
tion of the host immune system to the clinical outcome 
of these patients, taking advantage of the absence of 
anthracyclines-related toxicity [24]. We selected periph-
eral blood as the easiest source of biological samples and 
thus as the ideal candidate for our immunomonitoring 
analysis.
Herein we provide evidence indicating that, compared 
to partial responders, pCR patients were characterized by 
a more efficient functionality of both innate and adaptive 
immune cells, especially among HER2-positive patients. 
In particular, our results are consistent with a relevant 
contribution of circulating NK cells and TAA-specific 




This study, part of a phase II mono-institutional trial, 
included the analyses performed in blood samples 
obtained from 78 patients with histologically confirmed 
locally advanced breast carcinoma (defined as not sus-
ceptible of conservative surgery at diagnosis; UICC, 
International Union Against Cancer, stage II to III). HER2 
status was assessed by immunohistochemistry (IHC) 
and chromogenic in  situ hybridization (CISH) or fluo-
rescence in situ hybridization (FISH) in case of IHC 2+. 
All patients had the following clinical features: Eastern 
Cooperative Oncology Group performance status of 0 or 
1; baseline left ventricular ejection fraction measured by 
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ultrasonography greater than 50%; adequate organ func-
tion (bone marrow function: neutrophils ≥2.0 ×  109/L, 
platelets ≥120  ×  109/L; liver function: serum bilirubin 
<1.5 times the upper limit of normal (ULN), transami-
nases <2.5 times ULN, alkaline phosphatase ≤2.5 times 
ULN, serum creatinine <1.5 times ULN).
Patients with HER2-overexpressing locally advanced 
BC (n  =  40; median age of 46  years, range 23–70) 
received an anthracycline-free NC with Trastuzumab 
(loading dose 4  mg/kg intravenously, then 2  mg/kg 
weekly) and concomitant weekly Paclitaxel (80  mg/m2; 
[TP]) for 3 cycles, followed by evaluation and, in case 
of clinical response, 3 more cycles to obtain a pCR. The 
HER2-negative breast cancer group of patients (n = 38; 
median age of 46  years, range 27–69) was treated with 
a NC regimen containing both taxanes and anthracy-
clines (8 cycles of Docetaxel [75 mg/m2] and concomitant 
Epirubicin [90  mg/m2] every 3  weeks [ED]). Accord-
ing to RECIST criteria a total of 17 pCR (42.5%) were 
achieved in the HER2-positive arm and 5 (13.2%) within 
the HER2-negative group. After NC completion, patients 
underwent primary surgery (mastectomy or conservative 
treatment) as well as axillary node dissection. The breast 
conserving surgery rate was 37.5% (15/40) in HER2-posi-
tive patients and 42.1% (16/38) in HER2-negative.
Patients with progressive disease after the first evalua-
tion (12 weeks of treatment) underwent primary surgery 
and received adjuvant chemotherapy using different regi-
mens according to international guidelines. Instrumental 
evaluation was performed at baseline and every 12 weeks. 
This study (ClinicalTrials.gov Identifier: NCT02307227) 
was conducted according to the ethical principles of the 
Declaration of Helsinki and approved by the local Ethi-
cal Committee (Comitato Etico Indipendente del CRO 
di Aviano, May 29, 2006). Written informed consent was 
obtained from all patients and donors.
Sample collection
Blood and serum samples were collected from each 
patient at diagnosis and throughout NC, after 12 and 
24 weeks of treatment, and transported at room tempera-
ture. Peripheral blood mononuclear cells (PBMCs) were 
freshly isolated (within 5  h after blood drawing) from 
heparinised blood of patients by Ficoll-Hypaque gradi-
ent (Lymphoprep, Fresenius Kabi Norge Halden) using 
standard gradient separation. Cells were washed in PBS 
(Biomerieux), counted using Trypan blue (viability >90%) 
and viably frozen (90% heat-inactivated Fetal Bovine 
Serum [FBS; Gibco®, Life Technologies] and 10% DMSO) 
at −80°C for 24 h and then in liquid nitrogen until use. 
After thawing in RPMI-1640 medium (Sigma-Aldrich) 
with 3  μg/ml Deoxyribonuclease (Sigma-Aldrich), cells 
were washed in PBS (Biomerieux) and counted again to 
check viability (>80%). We included also 20 age-matched 
healthy women as controls, whose PBMCs were collected 
from buffy coat products and stored as described above. 
Patient’s and donor’s samples were genotyped to identify 
those expressing the allele HLA-A*0201 by performing 
PCR sequencing based typing with specific primers [25].
Peptide selection and synthesis
The following 13 immunogenic HLA-A*0201-restricted 
nonamer (9-mer) peptides, derived from different TAA 
were selected for the study: Mammaglobin-A LIY83-92 
LIYDSSLCDL, Survivin ELT95-104 ELTLGEFLKL, Sur-
vivin LDR104-113 LDRERAKNKI, Mucin-1 LLL12-20 
LLLLTVLTV, Mucin-1 STA950-958 STAPPVHNV, Her2/
neu KIF369-377 KIFGSLAFL, Her2/neu CLT789-797 CLT-
STVQLV, Her2/neu VLV851-859 VLVKSPNHV, Her2/
neu ELV971-979 ELVSEFSRM, Trag-3 HAC37-45 HACW-
PAFTV, Trag-3 SIL57-66 SILLRDAGLV, Bcl-xL RIA165-174 
RIAAWMATYL, and Bcl-xL YLN173-182 YLNDHLEPWI. 
The HLA-A*0201-restricted Flu matrix 1 (M1) GIL58-66 
peptide (GILGFVFTL) was used as the positive con-
trol in the IFN-γ ELISPOT assays, while the following 
mix of peptides derived from Cytomegalovirus- (CMV), 
Epstein-Barr Virus- (EBV), and Flu antigens was the pos-
itive control in dual color IFN-γ/IL-2 ELISPOT assays: 
CMV pp65 IPS113-121 IPSINVHHY, CMV pp65 TPR417-426 
TPRVTGGGAM, EBV BMLF1 GLC259-267 GLCTLVAML, 
EBV EBNA3B IVT416-424 IVTDFSVIK, EBV BRLF1 
ATI134-142 ATIGTAMYK, Flu M1 GIL158-66 GILGFVFTL, 
Flu NucleoProtein (NP) RVL342-351 RVLSFIKGTK, Flu 
M1 SII13-21 SIIPSGPLK, Flu NP ELR380-388 ELRSRYWAI. 
All peptides were produced by fluorenylmethoxycarbonil 
synthesis (Primm) and purity (>95%) was determined by 
reverse-phase high-performance liquid chromatogra-
phy and verified by mass spectral MALDI-TOF analysis. 
Peptides were dissolved in DMSO at a concentration of 
2.5 mg/ml and stored at −80°C until use. Work stocks for 
each peptide were prepared in PBS at a final concentra-
tion of 500 μg/ml and stored frozen.
Flow cytometry and multispectral imaging
The following fluorescent-conjugated monoclonal 
antibodies were used: α-CD3 fluorescein isothiocy-
anate (FITC) or phycoerythrin-texasred (ECD; mouse 
immunoglobulin (Ig) G1, clone UCHT1), α-CD4 phy-
coerythrin-cyanine5 (Pe-Cy5; mouse IgG1, 13B8.2), 
α-CD8 phycoerythrin-cyanine7 (Pe-Cy7; mouse IgG1, 
SFCI2IThy2D3), α-CD16 FITC (mouse IgG1, 3G8), 
α-CD19 FITC (mouse IgG1k, J3-119), α-CD25 ECD 
(mouse IgG2a, B1.49.9), and α-CD45RA ECD (mouse 
IgG1, 2H4LDH11LDB9) all from Beckman Coulter; 
α-CD56 phycoerythrin (PE; mouse IgG1k, B159) and 
α-CD197 PE (CCR7, rat IgG2a k, 3D12) purchased from 
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BD Biosciences (Becton–Dickinson); α-CD4 Pe-Cy7 
(mouse IgG1  k, RPA-T4), α-CD127 Pe-Cy5 (mouse 
IgG1, eBioRDR5), α-FoxP3 PE (Rat IgG2a k, PCH101), 
and α-Interleukin (IL) 17 FITC (mouse IgG1k, eBio-
64DEC17) from eBioscience; α-NF-κB p65 FITC (mouse 
IgG1, F-6) purchased from Santa Cruz Biotechnology, 
INC. DRAQ5™ fluorescent DNA dye from BioStatus Lim-
ited was used in nuclear localization analysis. Properly 
labelled isotypic antibodies were used as negative con-
trols. All antibodies were used in an appropriate volume 
of 10% rabbit serum (Dako) and PBS to reduce nonspe-
cific signal. Intracellular FoxP3 was determined using 
the eBioscience FoxP3 Staining Buffer Set (eBioscience) 
according to the manufacturer’s instructions. Briefly, after 
surface molecules staining, cells were fixed and permea-
bilized with fixation/permeabilization buffer for 30  min 
at 4°C, washed twice, and labelled with FoxP3 antibody in 
the presence of 2% rabbit serum in PBS at 4°C for at least 
30 min and, after two washes, cells were re-suspended in 
PBS with 1% paraformaldehyde. To evaluate IL-17 release, 
cells were pretreated with 25 ng/ml Phorbol 12-Myristate 
13-Acetate (PMA, Sigma-Aldrich) and 1 μg/ml Ionomy-
cin (Sigma-Aldrich) in the presence of 500 ng/ml Monen-
sin-A (Sigma-Aldrich) in complete medium (RPMI-1640 
[Sigma-Aldrich] supplemented with 10% FBS) for 4  h 
at 37°C. Cells were labelled for surface molecules, then 
fixed with 2% paraformaldehyde in complete medium for 
10 min at room temperature, washed in complete medium 
and permeabilized using 90% methanol diluted in H2O. 
After 10 min incubation in ice, cells were washed in per-
meabilization buffer (PBS with 0.5% Bovine Serum Albu-
min [BSA; Sigma-Aldrich]) and stained with 0.125 μg of 
α-IL-17 antibody in 2% rabbit serum diluted in permea-
bilization buffer at 4°C for 30 min. Samples were washed 
twice and re-suspended in PBS with 1% paraformaldehyde 
for flow cytometry analysis. At least 5 × 104 cells for sur-
face markers and 1  ×  106 cells for intracellular staining 
were acquired. Cytofluorimetric analysis was performed 
with a Cytomics FC500 (Beckman Coulter, Fullerton, CA, 
USA), photomultiplier voltages and compensation were 
set with unstained and stained cells. Data were analyzed 
with CXP (Beckman Coulter, Fullerton, CA, USA) and 
FlowJo (Tree Star, Ashland, OR, USA) softwares.
Immune cells subsets were identified as following 
(see Additional file  1): CD3+ T cells, CD19+ B cells, 
CD3−CD16+CD56+ NK cells, CD3+CD4+ T cells, 
CD3+CD8+ T cells, CD3+CD4+CD25+CD127−/lowFoxP3+ 
Treg cells, CD3+CD4+IL17+ Th17 cells. Among 
CD3+CD4+ and CD3+CD8+ T cells, CCR7+CD45RA+ 
naïve T cells (Tnaive), CCR7+CD45RA− Central Memory 
T (TCM) cells, CCR7−CD45RA− Effector Memory T cells 
(TEM), CCR7−CD45RA+ Terminally Differentiated T cells 
(TTemra) were identified.
Purified NK cells were obtained by immunomagnetic 
enrichment protocols using the human NK Cell Isola-
tion Kit (Miltenyi Biotec) according to manufacturer’s 
instructions.
To determine NF-κB nuclear internalization, purified 
NK cells (1.5 × 106) were labeled with α-NF-κB FITC and 
α-CD56 PE monoclonal antibodies. Briefly, after CD56 
staining in 10% rabbit serum, cells were fixed and per-
meabilized as described above at 4°C, washed twice, and 
labeled with NF-κB antibody (1:100) in PBS 2% rabbit 
serum for 45 min at 4°C. After two washes in PBS/0.5% 
BSA, cells were re-suspended in PBS with 1% paraform-
aldehyde and DRAQ5 DNA dye (5  µM). Cells were run 
on the ImageStreamX cytometer using the INSPIRE 
software (Amnis Corporation, Seattle, WA, USA) and 
images were analyzed using the IDEAS software (Amnis 
Corporation, Seattle, WA, USA). Cells were excited using 
a 488 nm laser with intensity of 40 mW. Brightfield, side 
scatter, fluorescent cell images were acquired at 40× 
magnification. Only events with brightfield areas greater 
than 20 μm2 (excluding debris) and non-saturating pix-
els were collected. NF-κB nuclear localization was meas-
ured using an IDEAS software feature, the Similarity 
Score (SS), that defines/quantifies the similarity of the 
nuclear (DRAQ5) and labelled-transcription factor stain-
ing patterns (NF-κB FITC). All events showing a positive 
SS were considered with high similarity between NF-κB 
and DRAQ5, thus indicating a nuclear localization of the 
transcription factor. Only viable cells were selected on 
the basis of morphologic features. Single-stained com-
pensation controls were used to compensate fluorescence 
between channel images on a pixel-by-pixel basis.
ADCC assay
The monoclonal antibody Trastuzumab acts through 
widely described immune-mediated mechanisms as 
the ADCC, which involve host’s immune cells [26]. 
The ADCC efficiency was evaluated in a Calcein-AM 
release assay, using the HER2/neu-overexpressing BC 
cell line MDA-MB453 as target cells, and patients’ 
PBMCs as effectors. The cell line was cultured in DMEM 
(Sigma-Aldrich), containing 2  mM l-glutamine, 10% 
FBS, 100  μg/ml streptomycin and 100  IU/ml penicillin 
(Sigma-Aldrich), at 37°C in 5% of CO2. One million tar-
get cells in exponential growth was labelled with 7.5 μM 
Calcein-AM (Molecular Probes) for 30  min at 37°C, 
washed 3 times, then incubated with Trastuzumab anti-
body (20 μg/ml; Roche) 1 h in ice. Without washing the 
persistence of soluble antibody, 1  ×  104 labelled-target 
cells per well were seeded into 96-well U-bottom plates. 
Experiments were conducted in triplicates at two effec-
tor (PBMCs):target ratios of 30:1 and 15:1, in 200 μl of 
Hank’s Balanced Salt Solution (HBSS) containing 5% 
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FCS. After 4 h at 37°C and 5% CO2 the release of Calcein 
(excitation  =  485  nm; emission  =  530  nm) was meas-
ured with a fluorescence plate reader (SpectraFluorPlus, 
Tecan, Männedorf, Switzerland). Maximal and spontane-
ous Calcein release values were obtained by adding either 
100 μl Lysis buffer (NaBO3 0.025 M, Triton X-100 0.1%, 
pH 9) or HBSS, to wells containing 1 × 104 labeled tar-
get cells. The percentage of lysis was calculated accord-
ing to the standard formula  =  100  ×  (experimental 
release − spontaneous release)/(maximal release − spon-
taneous release). The percentage of lysis was normalized 
for 10,000 NK cells using the following formula =  (per-
centage of lysis × 104)/(effector: target ratio × target cell 
no. in an experimental well × NK percentage in PBMCs) 
[27].
IFN‑γ and IFN‑γ/IL‑2 ELISPOT assay
The interferon (IFN)-γ release enzyme-linked immu-
nosorbent spot (ELISPOT) assay was performed using 
a commercial kit (Human IFN-γ ELISPOT; Thermo sci-
entific), according to manufacturer’s instructions. Briefly, 
the assay was carried out using autologous peptide-
pulsed monocytes as antigen presenting cells (APCs) and 
isolated CD8+ T lymphocytes as responders. Monocytes, 
isolated by a 2  h plastic adherence step from patient’s 
PBMCs, were loaded with 10 μg/ml of each 9-mer pep-
tide in complete medium, supplemented with 5  μg/ml 
of human β2-microglobulin (Sigma-Aldrich), and incu-
bated for 2 h at 37°C with 5% CO2. Purified effectors were 
obtained by immunomagnetic enrichment protocols 
using the human CD8+ T cell isolation kit II (Miltenyi 
Biotec), and then cultured with peptide-loaded mono-
cytes (50,000 cells/well) at 1:1 effector:target ratio. FLU 
M158-66 and unstimulated monocytes were used as posi-
tive and negative controls, respectively. Cells were seeded 
onto ELISPOT capture plates in triplicates and incubated 
for 48 h at 37°C with 5% CO2.
IFN-γ and IL-2 dual color ELISPOT assay (TriSpot 
Human IFN-γ/IL-2 ELISPOT kit, Endogen) was carried 
out by using PBMCs derived from 4 HLA-A*0201 BC 
patients. Briefly, PBMCs (200,000 cells/well) were plated 
and stimulated for 28 h, at 37°C and 5% CO2, with 4 µg/
ml of a panel of 4 out of the 13 TAA-derived peptides, 
previously validated by single color ELISPOT. The CEF 
mix was also used as positive control peptide stimuli. 
Media and PBMCs alone were used as negative controls, 
and the anti-CD3 antibody (clone UCHT1; BD Pharmin-
gen™) was used as a positive control stimulus.
All plates were evaluated by a computer-assisted ELIS-
POT reader (Eli.Expert, A.EL.VIS GmbH, Hannover, 
Germany; see Additional file  2 for representative wells 
pictures). The number of spots in negative control wells 
(range 0–5 spots) was subtracted from the number of 
spots in stimulated wells. Responses were considered 
significant if a minimum of five IFN-γ or IL-2 producing 
cells were detected in the wells.
Statistical methods
Data obtained from multiple independent experiments 
were expressed as mean and standard deviation for 
immunophenotypic analysis, ADCC assay, and NF-κB 
nuclear translocation experiments. Mean values were 
reported in IFN-γ and IFN-γ/IL-2 dual spot ELISPOT 
assays. Raw data can be provided per request. The Stu-
dent’s t test for two tailed distributions and paired data 
was used for the statistical analysis of variations dur-
ing NC in circulating immune cells percentages, NF-κB 
nuclear translocation levels, and percentages of lysis in 
ADCC assays, comparing data obtained at diagnosis 
with data measured respectively after 12 and 24 weeks of 
treatment. The Student’s t test for two tailed distributions 
and unpaired data was used to compare data regarding 
HER2-positive and HER2-negative arms, or patients 
achieving a pCR with partial responders within the single 
arms. Differences were considered statistically significant 
when P ≤ 0.05.
Laboratory environment
These studies were conducted in a laboratory that 
operates under exploratory research principles, using 
established laboratory protocols, and validated assays. 
Moreover, the laboratory gained the ISO 9001:2008 cer-
tification (Bureau Veritas agency) with the fulfillment 
of the ISO 9001:2008 accreditation criteria both for 
research and diagnostic procedures. The date of the last 
audit was January 13th, 2015.
Results
NC induced a reshuffle of circulating immune cells 
in HER2‑positive and HER2‑negative breast cancer patients
Our previous findings showed that, at diagnosis, locally 
advanced BC patients with a HER2-overexpressing malig-
nancy disclosed several differences in the distribution of 
circulating immune cells in comparison to HER2-nega-
tive BCs [23]. We thus wondered whether this different 
immune background might have influenced the response 
to NC and how chemotherapy treatment could affect 
immune cells distribution. In both groups of patients, 
the NC treatment induced a decrease in the number of 
circulating B cells, more pronounced in HER2-negative 
cases, an increase in the CD4/CD8 ratio, and a progres-
sive enlargement of the Treg cell compartment preceded 
by a parallel increase in the number of Th17 cells after 
12 weeks of treatment. As compared to the HER2-nega-
tive group, HER2-positive cases showed lower numbers 
of Th17 cells during NC, lower percentages of NK cells 
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and a higher CD4/CD8 ratio at week 12, and higher num-
bers of CD4+ Tnaive cells at the end of NC (Figure 1a and 
see Additional file  3). HER2-negative patients disclosed 
an increase in the percentage of T cells that, at the end 
of therapy, reached the levels observed in HER2-positive 
cases. Characterization of T cell memory phenotype 
revealed a raise in CD4+ Tnaive cells in both groups, bal-
anced by a decrease of CD4+ TTemra cells in the HER2-
positive group, and by a reduction of CD4+ TEM cell 
compartment in HER2-negative cases. Among CD8+ T 
cells, TCM decreased in both arms, while an increase in 
Tnaive appeared only in HER2-positive patients. NK cells 
displayed an opposite behavior in the 2 groups, with a 
significant increase in HER2-positive patients during TP 
therapy and an important drop in ED-treated HER2-neg-
ative patients (Figure 1a and see Additional file 3).
Possible correlations between the pathological 
response and changes in the proportions of circulating 
immune cells were then investigated in both groups of 
BC patients. Within the HER2-negative arm, correlations 
with the pathological response were already highlighted 
at diagnosis, with pCR patients showing lower numbers 
of B cells and NK cells, and higher percentages of T cells 
compared to partial responders (pPR). Differences in the 
number of T lymphocytes and NK cells were maintained 
till the end of ED therapy. A higher percentage of Treg 
was also documented in pCR cases compared to partial 
responders after 12  weeks of NC. Interestingly, no sig-
nificant changes were found in pCR patients throughout 
NC, while partial responders at the end of ED therapy 
showed decreased numbers of B cells and NK cells and an 
increase in T cells and CD4/CD8 ratio. In these patients, 
the number of Treg cells underwent a gradual increase 
that was paralleled by a boost in Th17 percentage at week 
12 (Figure 1b).
The only difference observed between pCR and pPR 
within HER2-positive patients was a significant increase 
in the percentage of Treg cells at diagnosis in patients 
who experienced a pCR. However, both pCR and pPR 
groups showed a progressive enlargement of this CD4+ 
T cell subset that was compensated by an enhanced pool 
of Th17 cells at week 12 only in pCR patients. The num-
ber of B cells significantly decreased in partial respond-
ers, whereas the CD4/CD8 ratio significantly heightened 
in pCR patients. Interestingly, TP treatment induced a 
significant increase in the number of NK independently 
from pathological response (Figure 1c).
Trastuzumab and Paclitaxel NC positively modulated 
innate immunity by boosting NK cells efficiency 
in HER2‑positive patients
Within the innate immunity compartment, we considered 
the pivotal role of NK cells in anti-tumor immunity and 
their contribution to the induction of clinical responses 
Figure 1 Phenotyping of circulating immune cells in HER2-negative and HER2-positive BC patients during NC. a Comparison of the percentage 
of several immune cell subsets quantified in the peripheral blood of HER-negative (white plots; n = 33) and HER2-positive (black plots; n = 23) BC 
patients throughout NC. *p < 0.05 comparing HER2-positive with HER2-negative patients. b Analysis of immune cell percentages within HER2-neg-
ative patients comparing individuals achieving a pathological complete response (pCR; black plots; n = 4) with those characterized by a pathologi-
cal partial response (pPR; white plots; n = 29). *p < 0.05 comparing pCR with pPR patients. c Immune cell percentages observed in HER2-positive 
patients undergoing a pCR (black plots; n = 11) and in HER2-positive patients showing a pPR (white plots; n = 12). *p < 0.05 comparing pCR with 
pPR patients. NK Natural Killer cells, Th17 T helper 17 cells, Treg regulatory T cells, W week, pCR pathological complete response, pPR pathological 
partial response; **p < 0.05 in respect to the corresponding diagnosis values.
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to drugs acting through immune-mediate mechanisms, 
such as Trastuzumab [16]. To investigate the role of NK 
cells in mediating the response to NC, we better charac-
terized the functionality of this cell subset by investigat-
ing the activation of the NF-κB transcription factor by 
Multispectral Flow Cytometry. This technique allows a 
precise enumeration of cells carrying a nuclear transloca-
tion of the p65 component of the complex, a marker of 
NF-κB activation (Figure 2d).
No differences in the percentage of NK cells with a 
nuclear translocation of p65 were highlighted between 
HER2-positive and HER2-negative patients at diagnosis 
and throughout NC treatment (Figure 2a). HER2-positive 
patients disclosed an increased percentage of cells with 
the NF-κB nuclear translocation during NC if compared 
to diagnosis levels (Figure  2a), whilst in the HER2-neg-
ative cohort this increase was evident only in patients 
undergoing a partial response (Figure  2c). Interestingly, 
Figure 2 NF-kB nuclear translocation in NK cells of HER2-positive and HER2-negative patients throughout NC. a Quantification of the nuclear 
translocation of NF-kB in NK cells of HER2-positive (HER2+; black dots; n = 12) and HER2-negative patients (HER2−; white dots; n = 10) at diagnosis 
and during NC, and in healthy donors (DONORS; gray dots; n = 10). b Analysis performed within HER2-positive patients comparing NF-kB nuclear 
translocation observed in NK cells of patients undergoing a pathological complete response (pCR, black dots; n = 5) with that measured in case 
of partial response (pPR, white dots; n = 7) throughout NC, and with levels found in healthy donors (gray dots; n = 10). *p < 0.05 comparing values 
observed in case of complete response with those measured in partial responders. c Comparison of NF-kB nuclear translocation observed in the 
NK cells of HER2-negative patients achieving a pathological Complete response (pCR, black dots; n = 3) with levels measured in NK cells of HER2-
negative partial responders (pPR, white dots; n = 7) during NC, and with the amount noticed in NK cells from healthy donors (gray dots; n = 10). 
d Representative plots obtained by Multispectral Flow Cytometry showing typical histograms of NK cells without (upper plot) or with (lower plot) 
the nuclear translocation of NF-kB. Representative cell pictures are shown. W week, pCR pathological complete response, pPR pathological partial 
response; **p < 0.05 in respect to the corresponding diagnosis values.
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within the HER2-positive arm, patients achieving a pCR 
displayed an enhanced percentage of NK cells character-
ized by NF-κB activation if compared to patients under-
going a partial response at diagnosis and throughout NC 
treatment, and in addition, diagnosis levels significantly 
increased during therapy only in case of pCR (Figure 2b).
NK cells are considered one of the main effectors trig-
gering Trastuzumab-mediated ADCC, a mechanism of 
action that seems to actively contribute to the induc-
tion of a clinical response to this drug [19]. We therefore 
run an in  vitro ADCC assay using patients’ PBMCs as 
effectors, and assessed the efficiency of Trastuzumab-
dependent ADCC lysis after normalization for NK 
cell numbers (10,000). This analysis was performed in 
patients affected by a HER2-overexpressing cancer and 
treated with Trastuzumab and taxol, and in a control 
group of age-matched healthy women. At diagnosis, 
both patients achieving a pCR and those characterized 
by a partial response showed lower ADCC levels com-
pared to healthy donors (not significant). However, pCR 
patients had a slightly higher ADCC efficiency than par-
tial responders (Table  1). The analysis of ADCC levels 
performed along NC treatment and compared to diag-
nosis values revealed a decreased ADCC efficiency (ratio 
<1) in both groups of patients. Nevertheless, while partial 
responders revealed a continuous decrease of normalized 
ADCC values till the end of treatment, in pCR cases we 
noticed an opposite trend after 12  weeks characterized 
by slightly enhanced ADCC levels (Table 1). Due to the 
wide variability of ADCC levels measured through this 
in  vitro assay, we highlighted no significant differences 
between the two groups of patients.
A more functional anti‑tumor adaptive immunity is 
maintained throughout NC in patients achieving a 
pCR compared to partial responders, especially in the 
HER2‑positive arm
Pre-existing T-cell responses against TAA have been 
reported in patients with solid tumors and BC, in par-
ticular. At diagnosis, we observed that the ability to stim-
ulate the generation of anti-tumor CD8+ T cells seemed 
to be more pronounced in HER2+ cancers [23]. We thus 
hypothesized that adaptive immunity might have a role 
in the response to NC, especially in the HER2-positive 
group of patients. Characterization of adaptive anti-
tumor immune responses in our cohorts of patients 
was carried out by IFN-γ ELISPOT assay of spontane-
ous CD8+ T cell responses to 13 HLA-A*0201-restricted 
peptides derived from 6 different TAA (Mammaglobin-
A, Survivin, Muc-1, HER2, Trag-3, Bcl-xL) [28–34] in 6 
HER2-positive and 7 HER2-negative patients expressing 
the HLA-A*0201 allele. CD8+ T cell responses against all 
these epitopes were detectable in both groups of patients 
throughout treatment, even if a generalized decrease in 
the amount of these responses was usually observed after 
12 weeks of treatment (Figure 3).
Interestingly, HER2-negative patients achieving a pCR 
(n = 2) showed a marked increase in the number of IFN-
γ-producing CD8+ T cells only after stimulation with 
Mammaglobin-A and Survivin-derived peptides if com-
pared to partial responders (n = 5), both at diagnosis and 
at the end of treatment (Figure 3a).
The same analysis performed in the HER2-positive arm 
revealed that, compared to partial responders (n  =  2), 
patients undergoing a pCR (n  =  4), displayed at diag-
nosis higher numbers of CD8+ T cells specific for all 
six TAAs investigated, in response to at least one of the 
derived epitopes (Figure 3b). Moreover, the prevalence of 
TAA-specific T cell responses in pCR patients was usu-
ally maintained throughout NC (Figure 3b). Interestingly, 
immunohistochemical analysis carried out in two rep-
resentative cases revealed a higher infiltration of CD8+ 
cells in the tumor microenvironment of a patient achiev-
ing a pCR compared to a partial responder (Additional 
file  4). Intriguingly, while TAA-specific T-cell responses 
were always detectable in pCR patients, after 12 weeks of 
treatment partial responders showed no detectable CD8+ 
T-cell responses against some of the Mammaglobin-A, 
Muc-1, Her2-, and Trag3-derived epitopes (Figure 3b).
To examine more in depth the functionality of TAA-
specific T-cells, we further investigated the simultane-
ous release of IFN-γ and IL-2 after stimulation with 
Table 1 In vitro Trastuzumab-mediated ADCC efficacy during NC in HER2-positive patients
NK Natural Killer cells, W week, SD standard deviation, pCR pathological complete response, pPR pathological partial response.
Diagnosis 12° W 24° W
Normalized values Ratio Ratio
% Lysis/10,000 NK % Normalized lysis 12°W/ 
% normalized lysis diagnosis
% Normalized lysis 24°W/ 
% normalized lysis diagnosis
Healthy women (n = 20) Mean ± SD (min–max) 23.13 ± 18.15 (5.06–90.68)
pCR patients (n = 14) Mean ± SD (min–max) 20.83 ± 18.00 (4.33–72.54) 0.52 ± 0.34 (0.15–1.26) 0.65 ± 0.38 (0.03–1.43)
pPR patients (n = 21) Mean ± SD (min–max) 16.63 ± 14.98 (0.00–46.70) 0.72 ± 0.38 (0.18–1.54) 0.58 ± 0.47 (0.00–1.25)
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TAA-derived peptides. The analysis was carried out for 
4 selected single epitopes (Mammaglobin-A LIY83-92, 
Survivin ELT95-104, Her2/neu ELV971-979, Bcl-xL YLN173-
182) (Figure  4a) and also considering together the T-cell 
responses against all the 4 different TAAs (Figure  4b). 
This latter evaluation revealed that, in the HER2-posi-
tive arm, the relative percentage of CD8+ T cells releas-
ing both cytokines in response to TAA-specific peptides 
was higher in patients achieving a pCR (n = 2) compared 
to partial responders (n  =  2), at the expense of single-
cytokine producing cells (Figure 4).
Discussion
The results of the present study extend our previous 
findings demonstrating that, at diagnosis, patients with 
locally advanced, HER2-overexpressing BC are charac-
terized by a retained immune proficiency [23], and more 
importantly, achieve a high rate of pCR (42.5%) after 
neoadjuvant Trastuzumab and Paclitaxel [35]. These 
observations, together with the known immune-modu-
lating effects of these drugs [36, 37], prompted us to thor-
oughly investigate the immune profile of the same cohort 
of patients along treatment. The time frame in which NC 
is administered is particularly suitable for immunological 
studies [36] because it does not suffer from the immune 
suppression induced by surgery or by advanced meta-
static disease.
We herein demonstrate that, in both groups of patients, 
NC treatment induced significant changes in the relative 
proportions of circulating immune cells. We first exam-
ined what happened within the innate immune compart-
ment, with particular attention to NK cells, given the 
major role of these immune cells in mediating the thera-
peutic effects of monoclonal antibodies such as Trastu-
zumab. NK cells showed an opposite behaviour in the two 
cohorts of patients, suggesting a different involvement of 
Figure 3 CD8+ T cell responses to BC-associated epitopes assessed by IFN-γ-ELISPOT in BC patients throughout NC. a Quantification of CD8+ T cell 
responses against 13 HLA-A*0201-restricted epitopes derived from 6 different BC-associated antigens (or against the flu matrix protein1-derived 
epitope) at diagnosis and during NC (12° and 24° week) in HER2-negative patients achieving a complete response (pCR, black dots; n = 2) and in 
those characterized by a partial response (pPR, white dots; n = 5). PHA-treated T cells and empty monocytes (EMPTY MONO) were used as positive 
and negative controls, respectively. b Analysis of CD8+ T cell responses against TAA-derived epitopes in HER2-positive patients reaching a complete 
response (pCR, black dots; n = 4) and a partial response (pPR, white dots; n = 2). SFC Spot Forming Cells, pCR pathological complete response, pPR 
pathological partial response, PHA phytohemagglutinin, Flu influenza, Mam-A Mammaglobin-A, Sur survivin, Muc mucin-1, Trag3 taxol resistance 
associated gene 3, W week.
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the innate responses in these two different tumor sub-
types. We have previously shown that, at diagnosis, the 
HER2-negative group had a higher percentage of circu-
lating NK cells than HER2-positive cases [23]. This NK 
cells prevalence was mainly found in HER2-negative 
partial responders, suggesting that this change is func-
tionally ineffective, being probably a consequence of the 
concomitant reduction in the T cell compartment. This 
altered balance between the NK and T cell pools could 
underlie an impairment of adaptive anti-tumor immune 
responses in HER2-negative patients unable to achieve a 
pCR. Nevertheless, we observed that the ED NC regimen 
induced a partial restoration of the balance between NK 
and T cells and was associated with an increased num-
ber of activated NK cells carrying nuclear translocation 
of NF-κB in partial responders, probably caused by the 
DNA-damage response induced by anthracyclines, able 
to alert the innate immune system against the tumor [36].
In contrast, HER2-positive patients showed progres-
sively increased NK cell percentages both in cases under-
going pCR and in partial responders, without evidence 
of concomitant alterations in the number of circulating 
Figure 4 Polyfunctional CD8+ T cell responses to BC-associated antigens assessed by DualSpot in HER2-positive patients during NC. a Representa-
tive histograms of the quantification of IFN-γ (gray bars), IL-2 (black bars), and IFN-γ/IL-2 (white bars) releasing CD8+ T cells after stimulation with 
four epitopes derived from four different BC-associated antigens obtained at diagnosis and during NC in one HER2-positive patient achieving a 
pathological complete response (BC87, pCR) and in one HER2-positive patient characterized by a partial response (BC105, pPR). Medium and PBMCs 
alone were used as negative controls, CEF and α–CD3 as positive controls. b Slices of cakes represent the means of the percentages of CD8+ T cells 
releasing IFN-γ (gray), IL-2 (black), or IFN-γ/IL-2 (white) after stimulation with all the four epitopes derived from BC-associated antigens in case of 
complete response (left) or partial response (right). SFC spot forming cells, pCR pathological complete response, pPR pathological partial response, W 
week, Sur survivin, Mam mammaglobin-A, CEF mix of peptides derived from Cytomegalovirus, Epstein-Barr virus, and influenza.
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T cells. Recent data convincingly demonstrated that 
taxanes are able to enhance T cell and NK cell functions 
[36, 38], and in  vitro experiments showed that Pacli-
taxel enhanced the cytotoxicity of human NK cells by 
increasing perforin production through NF-κB activa-
tion [39]. We herein showed a progressive and significant 
increase in the number of NK cells with activated NF-κB 
in HER2-positive patients, and in particular in those 
undergoing a pCR, suggesting a direct role of Paclitaxel 
treatment in mediating this effect. Intriguingly, the effi-
ciency of Trastuzumab-dependent ADCC, mainly due to 
NK lytic efficiency [15], at diagnosis was higher in pCR 
patients if compared to partial responders, and at the end 
of NC, pCR patients showed a slight recovery of normal-
ized ADCC lysis, whereas partial responders disclosed 
an opposite trend. However, the differences between the 
two groups of patients did not reach the statistical sig-
nificance probably due to the broad variability of ADCC 
activity, already observed through this kind of experi-
ments [40]. Larger series are thus required to estab-
lish whether the efficiency of Trastuzumab-dependent 
ADCC may constitute a marker predictive of pCR induc-
tion. However, the investigation of the innate immune 
compartment revealed a major role of NK cells in the 
cohort of patients treated with Trastuzumab, underlying 
a potential association between the increased activation 
state of these cells and the induction of a pCR.
Interestingly, Trastuzumab may also indirectly elicit a 
specific adaptive immune response, in particular against 
the HER2 TAA, by stimulating HER2-specific cytotoxic 
T cells through enhanced HER2 degradation, internaliza-
tion, and presentation by MHC-class I molecules [5, 37]. 
We thus quantified the amount of T cell responses spe-
cific for different epitopes derived from the HER2 pro-
tein during Trastuzumab-including NC. Although no 
increase in the number of HER2-specific T cell responses 
was observed in the time frame considered by this study, 
HER2-positive patients undergoing pCR, but not partial 
responders, maintained throughout NC a high preva-
lence of T cells specific for the same two HER2 epitopes 
recognized at higher levels at diagnosis. This suggests that 
retained T-cell responses against HER2 may favor the 
induction of a pCR in patients treated with Trastuzumab.
We then investigated the presence of anti-tumor adap-
tive immunity against other TAA usually expressed by 
different BC histotypes. One of the most relevant findings 
of the present study is the correlation between enhanced 
T cell responses against epitopes derived from Mamma-
globin-A and Survivin, detectable till the end of NC ther-
apy, and the induction of pCR in both HER2- positive and 
-negative subgroups. These results are consistent with a 
prevalent polarization of T-cell responses towards these 
antigens in BC, irrespective to the HER2 status of the 
tumor. Consistently with an enhanced immunogenicity 
of HER2-positive BC, patients with HER2-overexpressing 
tumors achieving a pCR showed an increased number of 
IFN-γ producing T cells after stimulation with peptides 
derived from a broader range of TAAs, which included 
in addition to HER2, Mammaglobin-A, and Survivin, also 
Muc-1, Trag3, and Bcl-XL. Notably, a higher prevalence 
of TAA-specific T cells producing both IFN-γ and IL-2 
was observed in these patients, thus suggesting a major 
clinical role of the multi-epitopic and polyfunctional 
anti-tumor T cell responses. In both groups of patients, 
TAA-specific T-cell responses decreased after the first 
12 weeks of NC. This is probably due to an initial immu-
nosuppressive effect of NC also favored by the corticos-
teroids premedication usually associated with taxane 
administration. Moreover, in any of the two groups of 
treatment we noticed a boosting of the anti-tumor T cell 
response during NC, even if both anthracyclines and tax-
anes have been associated with the induction of immu-
nogenic features [38, 41]. It can be argued that the time 
frame of NC is perhaps too short to observe an increase 
in peripheral anti-tumor T cell responses, particularly 
those generated de novo. Intriguingly, the increased pro-
portion of peripheral naïve T cells, observed at the end 
of NC among CD8+ T cells in the HER2-positive arm, 
may constitute a potential reservoir of T cell precur-
sors that may be primed at the tumor site, thus leading 
to the de novo generation of anti-tumor T cells. In addi-
tion, a representative immunohistochemistry analysis in 
two HER2-positive patients revealed a higher infiltration 
of CD8+ cells within the tumor microenvironment in 
case of pCR. Further in situ analyses may better investi-
gate the presence of an effective and increased immune 
response after NC, as described in other studies [8]. 
Finally, we are currently performing the same analysis in 
samples collected 2  months after surgery and at annual 
follow up, to assess whether anti-tumor T-cell responses 
measured during NC are lasting over time and able to 
generate immunological memory. This investigation will 
clarify the potential prognostic role of an effective anti-
tumor adaptive immunity in BC patients undergoing NC.
The efficiency of anti-tumor T cells may be widely influ-
enced by several immunosuppressive mechanisms devel-
oped by the tumor itself or induced in the host through 
the expansion of immunosuppressive cell subsets. With 
regard to Treg cells, several clinical studies revealed that 
the depletion of circulating Treg induced by cyclophos-
phamide-based NC reflected within the tumor micro-
environment [11], and their in situ absence after NC was 
associated with higher pCR rates in BC patients [42, 43]. 
In both our cohorts of patients after cyclophosphamide-
free NC we observed an increase in circulating Treg per-
centages that may have contributed to inhibit the boosting 
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of anti-tumor T cell responses. This observation strongly 
encourages to carefully consider the immune-modulation 
properties of conventional chemotherapy when designing 
the NC schedule [13], especially in the presence of Tras-
tuzumab. The stimulation of anti-tumor T cell responses 
promoted by this antibody may indeed benefit from the 
inhibition of tumor-induced immune suppression [18, 44].
Trastuzumab is also able to disrupt the balance 
between Treg and Th17, enhancing Th17 percentages 
during treatment and reducing Treg compartment in 
case of metastasis [22]. Our data interestingly highlighted 
a significant increase in the proportion of Th17 cells after 
12 weeks of treatment only in case of pCR, thus support-
ing the involvement of the Treg/Th17 ratio in mediating 
the response to NC in this setting.
In addition, intratumor and circulating Th17 cells were 
associated with improved prognosis and clinical response 
to therapy in BC [11, 45] and in  vivo data suggested the 
occurrence of a strict cooperation between Th17 cells and 
CD8+ cytotoxic T lymphocytes in mediating effective anti-
tumor immune responses [46]. In our analysis, especially 
in HER2-positive patients achieving a pCR, we noticed a 
significant increase in the number of Th17 cells at week 12 
of NC treatment that was usually followed (at week 24) by 
an enhancement of TAA-specific CD8+ T cell responses.
Conclusions
In conclusion, our data strongly support the relevance of 
immune-related factors in mediating the response of BC 
patients to NC treatment [18], and the independence of 
immunological parameters from classical predictive mark-
ers [13]. The integrated immunomonitoring performed in 
this study revealed that the peripheral immune function 
may constitute a valid source of suitable predictive bio-
markers in the NC setting. In particular, in HER2-positive 
patients treated with Trastuzumab and taxanes, the assess-
ment of NK cell activation and functionality throughout 
NC may become a strategy to identify patients more likely 
achieving a pCR. The analysis of adaptive anti-tumor T-cell 
responses against selected TAAs may instead constitute a 
powerful tool to identify, since the time of diagnosis, which 
patients will reach a pCR after NC in both HER2-negative 
and HER2-positive background. Finally, the increased per-
centage of Tregs, balanced by the Th17 enhancement only 
early on during the NC treatment, prompts to consider 
alternative combinations in the NC schedule that favor the 
reversion of cancer-related immune suppression, strength-
ening host anti-tumor immune responses and increas-
ing the likelihood to reach a pCR. The preliminary results 
obtained with the present study may thus favor the identi-
fication of relevant immune biomarkers, whose validation 
is warranted by further prospective clinical trials.
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